跳至主要内容
临床试验/NCT01164852
NCT01164852已完成不适用

Expectant Management of Severe Preeclampsia at 28 to 33 Week's Gestation:a Randomized Controlled Trial

Complejo Hospitalario Dr. Arnulfo Arias Madrid8 个研究点 分布在 6 个国家目标入组 264 人开始时间: 2010年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
264
试验地点
8
主要终点
Perinatal death

研究概览

简要总结

How best to manage preeclampsia remote from term is controversial because of conflicting maternal and neonatal risks. Gestational age is the most important determinant of neonatal outcome. There are two basic approaches when delivery is not clear indicated by assessment of maternal and fetal well-being. The interventionist care when the delivery is planned within 48 hours and the expectant care which refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.

The purpose of this study is to evaluate maternal and perinatal outcomes with expectant vs interventionist or aggressive management of severe preeclampsia at 28 to 33 weeks of gestation.

详细描述

Severa Preeclampsia between 28 and 33 weeks of gestation Women and fetus with stable condition All women receive complete dosis of steroids

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • Pregnancy with severe preeclampsia and 28 to 33 weeks of gestation

排除标准

  • Uncontrollable blood pressure or persistent severe hypertension (160/110 mmHg)
  • Persistent symptoms of preeclampsia
  • Maternal complications (HELLP syndrome, acute renal insufficiency, cerebral edema, eclampsia, pulmonary edema)
  • Fetal death, restriction of fetal grown

结局指标

主要结局

Perinatal death

时间窗: After begining the randomization until 4 weeks after delivery.

Number of perinatal in each group (interventionist or expectant management)

次要结局

  • Perinatal complications and maternal complications(Maternal and perinatal complication after begining the randomization until 4 weeks after delivery.)

研究者

发起方
Complejo Hospitalario Dr. Arnulfo Arias Madrid
申办方类型
Other
责任方
Principal Investigator
主要研究者

Paulino Vigil-De Gracia

Paulino Emilio Vigil De Gracia

Complejo Hospitalario Dr. Arnulfo Arias Madrid

研究点 (8)

Loading locations...

相似试验